

# Clinical information for vaccine consenters: Pfizer, AstraZeneca, Moderna vaccines

**DISCLAIMER:** Information within this document may be updated before the PGD or Protocol you are working under. In the event of a discrepancy, always adhere to your PGD/Protocol.

This document is regularly updated; please download the most recent version:

[https://ncl-mon.nhs.uk/wp-content/uploads/0\\_COVID\\_vaccine\\_Information\\_for\\_vaccinators.pdf](https://ncl-mon.nhs.uk/wp-content/uploads/0_COVID_vaccine_Information_for_vaccinators.pdf)



Key references.....	3
1 Assessing for primary-schedule vaccine appropriateness .....	4
2 Administration & dosing .....	5
2.1 Dosing schedule (timing and brands) .....	5
2.2 Overseas vaccinations .....	5
2.3 Vaccine administration error .....	5
2.4 Vaccine eligibility: adults (from 17 ¾ years) .....	6
2.5 Vaccine eligibility: 16 to 17 ¾ years .....	7
2.6 Vaccine eligibility: 12 to <16 years .....	8
2.7 Vaccine eligibility: <12 years .....	8
3 History of allergy or anaphylaxis .....	9
3.1 History of allergy (inc. anaphylaxis) before first dose .....	9
3.2 Allergy to first dose of COVID-19 vaccine .....	9
4 Cautions and contraindications .....	10
4.1 General information .....	10
4.2 Capillary Leak Syndrome .....	10
4.3 Glucose-6-phosphate dehydrogenase (G6PD) deficiency .....	10
4.4 Lymphoedema .....	11
4.5 Drug interactions.....	11
4.6 Recent or imminent elective surgery .....	11
4.7 Religious beliefs (Jewish and Muslim communities) .....	11
5 Adverse effects .....	12


5.1	Common and important adverse effects.....	12
5.2	Bell's Palsy .....	12
5.3	Guillain-Barré Syndrome.....	12
5.4	Risk of blood clots with lowered platelets (AstraZeneca vaccine).....	12
5.5	Myocarditis and pericarditis (Pfizer and Moderna vaccines).....	13
6	Excipients .....	14
6.1	List of excipients .....	14
6.2	Alcohol content .....	14
6.3	Vegan friendly or vegetarian? .....	14
7	Pregnancy and breastfeeding .....	15
7.1	Pregnancy .....	15
7.2	Breastfeeding.....	15
7.3	Implications for fertility & IVF programmes.....	15
8	Interactions .....	16
8.1	Vaccine interactions.....	16
8.2	Patient taking immunosuppressants .....	16
8.3	Alcohol.....	17
9	Other questions.....	18
9.1	Implications for blood donation .....	18
10	Management of patients recruited into trials .....	19
10.1	COV002 (Oxford) trial .....	19
10.2	COVAC1 (Imperial) trial .....	19
10.3	NOVOVAX trial .....	19
10.4	ENSEMBLE2 trial (Janssen; Johnson & Johnson; Ad26.COV2.S).....	20
10.5	Cov-Compare trial (Valneva; VLA2001) .....	20
10.6	COM-COV2 .....	21
10.7	Novavax study .....	21
11	Vaccine brands available nationally and internationally .....	22
12	Document management .....	24
13	Version history.....	24
	References .....	25

## Key references

- Summary of product characteristics:
  - [AstraZeneca vaccine](#)
  - [Pfizer/BioBTech vaccine: Information for Healthcare Professionals](#)
  - [Moderna vaccine](#)
- Specialist Pharmacy Service: Answers to Questions specific to vaccines
  - [General information](#)
  - Vaccine specific information
    - [Pfizer/BioNTech](#)
    - [AstraZeneca](#)
    - [Moderna](#)
- [Immunisation against infectious disease: Chapter 14a – COVID-19](#) (The Greenbook)
- [COVID-19 vaccination programme: Information for healthcare practitioners](#)

# 1 Assessing for primary-schedule vaccine appropriateness

This tool should only be used once the decision to offer a vaccine has been made. It supports clinicians in confirming whether a given vaccine is appropriate for a given individual. It does not consider vaccine eligibility (JCVI criteria) or contraindications to vaccination (e.g. acutely unwell).



## 2 Administration & dosing

2.1 Dosing schedule (timing and brands)	<p><a href="https://www.sps.nhs.uk/articles/dosing-information-for-covid-19-vaccines/">https://www.sps.nhs.uk/articles/dosing-information-for-covid-19-vaccines/</a></p> <p>Includes:</p> <ul style="list-style-type: none"><li>• Dosing schedule (recommended interval between 1<sup>st</sup> and 2<sup>nd</sup> dose)</li><li>• Longer interval than recommended</li><li>• Shorter interval than recommended</li><li>• Different brand for second dose</li></ul>
2.2 Overseas vaccinations	<p>See 'Individuals who received COVID vaccination overseas' (pg 14) and Appendix 1 <a href="https://www.gov.uk/government/publications/covid-19-vaccination-programme-guidance-for-healthcare-practitioners">https://www.gov.uk/government/publications/covid-19-vaccination-programme-guidance-for-healthcare-practitioners</a></p> <p>Patients should be asked to contact their GP surgery so that their overseas vaccinations can be recorded on their healthcare record.</p>
2.3 Vaccine administration error	<p>See 'Inadvertent vaccine administration errors' <a href="https://www.gov.uk/government/publications/covid-19-vaccination-programme-guidance-for-healthcare-practitioners">https://www.gov.uk/government/publications/covid-19-vaccination-programme-guidance-for-healthcare-practitioners</a></p> <p>This provides advice for inadvertent administration of:</p> <ul style="list-style-type: none"><li>• The whole multi-dose vial</li><li>• Over-diluted vaccine</li><li>• Incomplete dose of vaccine</li><li>• Vaccine which was subject to storage or preparation error</li></ul>

<p>2.4 Vaccine eligibility: adults (from 17 <sup>3</sup>/<sub>4</sub> years)</p>	<p>Eligibility criteria <sup>a</sup>:</p> <ul style="list-style-type: none"> <li>• Primary schedule: <ul style="list-style-type: none"> <li>○ First dose: All.</li> <li>○ Second dose: All</li> <li>○ Third dose: Only those who had severe immunosuppression in proximity to their first or second COVID-19 doses in the primary schedule (Box) <sup>b</sup></li> </ul> </li> <li>• Booster <ul style="list-style-type: none"> <li>○ those living in residential care homes for older adults</li> <li>○ all adults aged 50 years or over</li> <li>○ frontline health and social care workers</li> <li>○ all those aged 16 to 49 years with underlying health conditions that put them at higher risk of severe COVID-19 (Table 3) <sup>c</sup></li> <li>○ adult carers (Table 3<sup>c</sup>) and those experiencing homelessness</li> <li>○ adult household contacts of immunosuppressed individuals (Table 3<sup>c</sup>)</li> </ul> </li> </ul> <p><sup>a</sup> Advice for individuals aged 18-29 “includes those turning 18 years of age in the next three months” Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p> <p><sup>b</sup> Box, Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p> <p><sup>c</sup> Table 3, Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p>
--	--

<p>2.5 Vaccine eligibility: 16 to 17 <math>\frac{3}{4}</math> years</p>	<p>Eligibility criteria:</p> <ul style="list-style-type: none"> <li>• Primary schedule: <ul style="list-style-type: none"> <li>○ First dose: All</li> <li>○ Second dose: <ul style="list-style-type: none"> <li>▪ employed/studying/training for health and social care work <sup>a</sup></li> <li>▪ underlying health conditions that put them at higher risk of severe COVID-19<sup>b</sup></li> <li>▪ share living accommodation on most days with individuals of any age who are immunosuppressed <sup>c</sup></li> </ul> </li> <li>○ Third dose: Only those who had severe immunosuppression in proximity to their first or second COVID-19 doses in the primary schedule (Box)<sup>d</sup></li> </ul> </li> <li>• Booster: <ul style="list-style-type: none"> <li>○ frontline health and social care workers</li> <li>○ underlying health conditions that put them at higher risk of severe COVID-19 (Table 3) <sup>b</sup></li> <li>○ adult carers (Table 3<sup>b,e</sup>) and those experiencing homelessness <sup>e</sup></li> <li>○ adult household contacts of immunosuppressed individuals (Table 3<sup>b,e</sup>)</li> </ul> </li> </ul> <p><sup>a</sup> Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p> <p><sup>b</sup> Table 3, Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p> <p><sup>c</sup> Table 3 &amp; 4, Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p> <p><sup>d</sup> Box, Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p> <p><sup>e</sup> RVOC confirmed on 09/11/2021 that if the 16 to 17 <math>\frac{3}{4}</math> year olds were vaccinated as part of a priority group in Phase 1 of the COVID-19 vaccination programme, then they will be eligible for a booster. 'Adult carers' 'adults experiencing homelessness' and 'adult household contacts of immunosuppressed individuals' are all JCVI Priority Group 6 (Phase 1) which includes "adults aged 16 to 65 years" and therefore are eligible.</p>
---	--

<p>2.6 Vaccine eligibility: 12 to &lt;16 years</p>	<p>Eligibility criteria:</p> <ul style="list-style-type: none"> <li>• Primary schedule <ul style="list-style-type: none"> <li>○ First dose: All</li> <li>○ Second dose: <ul style="list-style-type: none"> <li>▪ underlying health conditions that put them at higher risk of severe COVID-19 (Table 4)<sup>a</sup></li> <li>▪ share living accommodation on most days with individuals of any age who are immunosuppressed (Box)<sup>b</sup></li> </ul> </li> <li>○ Third dose: Only those who had severe immunosuppression in proximity to their first or second COVID-19 doses in the primary schedule<sup>c</sup></li> </ul> </li> <li>• Booster: Nil</li> </ul> <p><sup>a</sup> Table 4, Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p> <p><sup>b</sup> Table 3 &amp; 4, Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p> <p><sup>c</sup> Box, Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p>
<p>2.7 Vaccine eligibility: &lt;12 years</p>	<p>Eligibility criteria:</p> <ul style="list-style-type: none"> <li>• First dose: Nil</li> <li>• Second dose: Nil</li> <li>• Booster: Nil</li> </ul>



### 3 History of allergy or anaphylaxis

3.1 History of allergy (inc. anaphylaxis) before first dose	<p>Follow North Central London flow diagram – Page 1 <a href="https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/0_Managing_Allergy_COVID-19_vaccine.pdf">https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/0_Managing_Allergy_COVID-19_vaccine.pdf</a></p> <p>Further information (including excipients and approach to prior history of allergy [latex, food, thiomersal, medicines]):</p> <ul style="list-style-type: none"><li>• Pfizer: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-pfizer-biontech/">https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-pfizer-biontech/</a></li><li>• AstraZeneca: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-astrazeneca/">https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-astrazeneca/</a></li><li>• Moderna: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-moderna/">https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-moderna/</a></li></ul>
3.2 Allergy to first dose of COVID-19 vaccine	<p>Follow North Central London flow diagram – Page 2 <a href="https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/0_Managing_Allergy_COVID-19_vaccine.pdf">https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/0_Managing_Allergy_COVID-19_vaccine.pdf</a></p>

## 4 Cautions and contraindications

4.1 General information	<p><a href="https://www.sps.nhs.uk/home/covid-19-vaccines/general-information-and-guidance/answers-to-questions/#cautions-and-contraindications">https://www.sps.nhs.uk/home/covid-19-vaccines/general-information-and-guidance/answers-to-questions/#cautions-and-contraindications</a></p> <p>Separate pages for:</p> <ul style="list-style-type: none"><li>• Anticoagulation and bleeding disorders</li><li>• Blood clots with COVID-19 vaccination (also see <a href="#">Green Book Chapter 14a</a> 'Thrombosis and thrombocytopenia occurring after COVID-19 vaccination')</li><li>• Acute severe febrile illness</li><li>• History of COVID-19</li><li>• Extremes of body weight</li><li>• Concurrent immunosuppressive medicines</li><li>• Extremes of bodyweight</li><li>• Porphyria</li></ul>
4.2 Capillary Leak Syndrome	<p>Do not use AstraZeneca vaccine in patients who have previously experienced episodes of capillary leak syndrome <sup>a</sup> (offer an alternative <sup>1</sup>).</p> <p><sup>a</sup> <a href="https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting">https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting</a> (28 October 2021)</p>
4.3 Glucose-6-phosphate dehydrogenase (G6PD) deficiency	<p>G6PD deficiency is not a contraindication to routine immunisation <sup>a</sup></p> <p><sup>a</sup> <a href="https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6">https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6</a></p>

4.4 Lymphoedema	<p>The vaccine is advisable for patients with lymphoedema <sup>a</sup>:</p> <ul style="list-style-type: none"> <li>• One arm affected by lymphoedema: Both doses of COVID-19 vaccine should be given in the unaffected, opposite arm.</li> <li>• Lymph nodes removed from the axilla (armpit) of one arm: Both doses of COVID-19 vaccine should be given in the opposite arm.</li> <li>• Both arms are affected by lymphoedema, but not the legs: Both doses of COVID-19 vaccine should be given into one of the thighs.</li> <li>• Both arms and one leg is affected by lymphoedema: Both doses of COVID-19 vaccine should be given into the unaffected thigh.</li> <li>• Both arms and both legs are affected by lymphoedema: Both doses of COVID-19 vaccine should be given into the limb least affected by lymphoedema</li> </ul> <p>Lymph node swelling is a known side effect of all the COVID-19 vaccines. It should resolve promptly after the vaccination. <sup>a</sup></p> <p><sup>a</sup> <a href="https://www.lymphoedema.org/wp-content/uploads/2021/05/Consensus_Document_on_COVID_Vaccination_amended_25May2021.pdf">https://www.lymphoedema.org/wp-content/uploads/2021/05/Consensus_Document_on_COVID_Vaccination_amended_25May2021.pdf</a> (25 May 2021)</p>
4.5 Drug interactions	See <a href="#">Interactions</a>
4.6 Recent or imminent elective surgery	<a href="https://www.sps.nhs.uk/articles/use-of-covid-19-vaccine-in-people-with-recent-or-imminent-elective-surgery/">https://www.sps.nhs.uk/articles/use-of-covid-19-vaccine-in-people-with-recent-or-imminent-elective-surgery/</a>
4.7 Religious beliefs (Jewish and Muslim communities)	<p>Pfizer: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-religious-or-other-dietary-practices-and-beliefs-on-their-suitability-for-the-covid-19-vaccine-pfizer-biontech/">https://www.sps.nhs.uk/articles/advising-individuals-with-religious-or-other-dietary-practices-and-beliefs-on-their-suitability-for-the-covid-19-vaccine-pfizer-biontech/</a></p> <p>AstraZeneca: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-religious-or-other-dietary-practices-and-beliefs-on-their-suitability-for-the-covid-19-vaccine-astrazeneca/">https://www.sps.nhs.uk/articles/advising-individuals-with-religious-or-other-dietary-practices-and-beliefs-on-their-suitability-for-the-covid-19-vaccine-astrazeneca/</a></p> <p>Moderna: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-religious-or-other-dietary-practices-and-beliefs-on-their-suitability-for-the-covid-19-vaccine-moderna/">https://www.sps.nhs.uk/articles/advising-individuals-with-religious-or-other-dietary-practices-and-beliefs-on-their-suitability-for-the-covid-19-vaccine-moderna/</a></p>

## 5 Adverse effects

5.1 Common and important adverse effects	See PHE patient information leaflet 'What to expect after your COVID-19 vaccination' <a href="https://www.gov.uk/government/publications/COVID-19-vaccination-what-to-expect-after-vaccination">https://www.gov.uk/government/publications/COVID-19-vaccination-what-to-expect-after-vaccination</a>
5.2 Bell's Palsy	The number of reports of facial paralysis received so far is similar to the expected natural rate and does not currently suggest an increased risk following the vaccines. <sup>a</sup>  <sup>a</sup> <a href="https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting">https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting</a> (28 October 2021)
5.3 Guillain-Barré Syndrome	Refer to Green Book for vaccine specific information (search GBS) <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a>
5.4 Risk of blood clots with lowered platelets (AstraZeneca vaccine)	See 'Risk of blood clots with COVID-19 vaccination' <a href="https://www.sps.nhs.uk/articles/covid-19-vaccination-and-blood-clotting/">https://www.sps.nhs.uk/articles/covid-19-vaccination-and-blood-clotting/</a>  To understand an individual's risk/benefit of vaccination with AstraZeneca vaccines, offer PHE patient information leaflet 'COVID-19 vaccination and blood clotting' <a href="https://www.gov.uk/government/publications/covid-19-vaccination-and-blood-clotting">https://www.gov.uk/government/publications/covid-19-vaccination-and-blood-clotting</a>  For signs and symptoms of clots with lowered platelets, offer PHE patient information leaflet 'What to expect after your COVID-19 vaccination' <a href="https://www.gov.uk/government/publications/COVID-19-vaccination-what-to-expect-after-vaccination">https://www.gov.uk/government/publications/COVID-19-vaccination-what-to-expect-after-vaccination</a>  For people worried about receiving a second dose of AstraZeneca vaccine, offer PHE patient information leaflet 'COVID-19 vaccination: worried about having your second dose of AstraZeneca?' <a href="https://www.gov.uk/government/publications/covid-19-vaccination-worried-about-having-your-second-dose-of-astrazeneca">https://www.gov.uk/government/publications/covid-19-vaccination-worried-about-having-your-second-dose-of-astrazeneca</a>

<p>5.5 Myocarditis and pericarditis (Pfizer and Moderna vaccines)</p>	<p>Myocarditis and pericarditis, inflammation of the heart. These reports are extremely rare, and the events are typically mild with individuals usually recovering within a short time with standard treatment and rest. <sup>a</sup> The reporting rate for myocarditis and pericarditis events is highest in the 18-49-year age group for all of the COVID-19 vaccines; there is currently no indication of an increased risk of these events in the under 18 years age group. <sup>a</sup></p> <p>Patients who experiences new onset of symptoms should seek medical attention. <sup>b</sup></p> <p>As the mechanism of action and risk of recurrence of myocarditis and pericarditis are being investigated, the current advice is that an individual's second or subsequent doses should be deferred until further information becomes available; an alternate vaccine may not reduce any risk of recurrence and will increase the likelihood of local and systemic reactions.</p> <p><sup>a</sup> <a href="https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting">https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting</a> (28 October 2021)</p> <p><sup>b</sup> <a href="https://www.gov.uk/government/publications/COVID-19-vaccination-what-to-expect-after-vaccination">https://www.gov.uk/government/publications/COVID-19-vaccination-what-to-expect-after-vaccination</a></p> <p><sup>c</sup> Green Book Chapter 14 <a href="https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a">https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a</a></p>
---	--

## 6 Excipients

6.1 List of excipients	<p>See 'Excipients'</p> <ul style="list-style-type: none"> <li>• Pfizer: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-pfizer-biontech/">https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-pfizer-biontech/</a></li> <li>• AstraZeneca: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-astrazeneca/">https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-astrazeneca/</a></li> <li>• Moderna: <a href="https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-moderna/">https://www.sps.nhs.uk/articles/advising-individuals-with-allergies-on-their-suitability-for-covid-19-vaccine-moderna/</a></li> </ul>
6.2 Alcohol content	<ul style="list-style-type: none"> <li>• Pfizer: No alcohol</li> <li>• Moderna: No alcohol</li> <li>• AstraZeneca: There is a very small amount of alcohol in the vaccine (0.002 g per dose).<sup>2</sup> This is not enough to cause any noticeable effects and is less than the amount of alcohol found in bread, vinegar and fruit juice.<sup>a</sup> The British Islamic Medical Association recommends the AstraZeneca vaccine<sup>b</sup></li> </ul> <p><sup>b</sup> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421578/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421578/</a></p> <p><sup>b</sup> <a href="https://britishima.org/covid19-vaccine-az/">https://britishima.org/covid19-vaccine-az/</a></p>
6.3 Vegan friendly or vegetarian?	<p>The approved COVID-19 vaccines do not contain any animal, meat or egg products <sup>3</sup></p> <p><a href="#">VeganFriendly</a> believe COVID-19 vaccines are vegan. <a href="#">PeTA</a> recommends that vegan and animal rights campaigners take up the vaccines.</p>

## 7 Pregnancy and breastfeeding

7.1 Pregnancy	<p><a href="https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-women-of-child-bearing-potential/">https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-women-of-child-bearing-potential/</a></p> <p><b>Useful resources when consenting:</b></p> <ul style="list-style-type: none"> <li>• PHE patient information leaflet: <a href="#">Women of childbearing age, currently pregnant or breastfeeding</a></li> <li>• RCOG Q&amp;A: <a href="https://www.rcog.org.uk/en/guidelines-research-services/coronavirus-covid-19-pregnancy-and-womens-health/covid-19-vaccines-and-pregnancy/covid-19-vaccines-pregnancy-and-breastfeeding/">https://www.rcog.org.uk/en/guidelines-research-services/coronavirus-covid-19-pregnancy-and-womens-health/covid-19-vaccines-and-pregnancy/covid-19-vaccines-pregnancy-and-breastfeeding/</a></li> <li>• RCOG Decision aid: <a href="https://www.rcog.org.uk/globalassets/documents/guidelines/2021-02-24-combined-info-sheet-and-decision-aid.pdf">https://www.rcog.org.uk/globalassets/documents/guidelines/2021-02-24-combined-info-sheet-and-decision-aid.pdf</a></li> </ul> <p><b>Recording vaccination during pregnancy:</b></p> <ul style="list-style-type: none"> <li>• <i>Where woman is known to be pregnant when vaccinated (1<sup>st</sup> or 2<sup>nd</sup> dose):</i> <ul style="list-style-type: none"> <li>○ Consenter should record pregnancy status on Pinnacle/NIVS, <b>and</b></li> <li>○ Invite woman to register with the <a href="#">Yellow Card Vaccine Monitor</a></li> </ul> </li> <li>• <i>Where woman did not know she was pregnant when vaccinated, or became pregnant shortly after vaccination:</i> <ul style="list-style-type: none"> <li>○ HCP who the pregnant women presents to should complete <a href="#">Inadvertent vaccination in pregnancy</a> notification</li> </ul> </li> </ul> <p><b>Legal mechanism for administration:</b></p> <ul style="list-style-type: none"> <li>• PSD, PGD and NP</li> </ul>
7.2 Breastfeeding	<p><a href="https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-breastfeeding-women/">https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-breastfeeding-women/</a></p> <p><b>Useful resources when consenting:</b></p> <ul style="list-style-type: none"> <li>• PHE patient information leaflet: <a href="#">Women of childbearing age, currently pregnant or breastfeeding</a></li> </ul>
7.3 Implications for fertility & IVF programmes	<p><a href="https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-women-of-child-bearing-potential/">https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-women-of-child-bearing-potential/</a></p>

## 8 Interactions

8.1 Vaccine interactions	<a href="https://www.sps.nhs.uk/articles/interactions-information-for-covid-19-vaccines/">https://www.sps.nhs.uk/articles/interactions-information-for-covid-19-vaccines/</a>
8.2 Patient taking immunosuppressants	<a href="https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-patient-taking-immunosuppressive-medicines/">https://www.sps.nhs.uk/articles/using-covid-19-vaccines-in-patient-taking-immunosuppressive-medicines/</a> <ul style="list-style-type: none"><li>• Scheduled to begin immunosuppressive therapy</li><li>• Treated with<ul style="list-style-type: none"><li>○ Chemotherapy</li><li>○ Corticosteroids</li><li>○ Rituximab (oncology)</li><li>○ Rituximab (rheumatology)</li><li>○ Multiple sclerosis</li></ul></li></ul>



8.3 Alcohol	<p>Some news and social media have reported you should abstain from alcohol to boost your immune response to the vaccine. This is selective reporting from a statement from DrinkAware (a UK alcohol education charity).<sup>a</sup> Their detailed recommendations:</p> <ul style="list-style-type: none"> <li>• Get vaccinated if you are offered a COVID-19 vaccine, <i>regardless of whether you ever drink any alcohol or not.</i></li> <li>• Heavy drinkers have a higher risk of becoming seriously ill with COVID-19 <i>therefore please keep your appointment for vaccination if you are offered one</i></li> <li>• There is no direct evidence that heavy or social drinking will affect your body's response to the COVID-19 vaccine</li> <li>• It is possible, but not proven, that drinking alcohol, especially regular heavy drinking, can reduce your body's response to some vaccines. Therefore it is prudent for you not to drink any alcohol for a few days before, and for at least two weeks after, you've been vaccinated.</li> </ul> <p>Summary:</p> <ul style="list-style-type: none"> <li>• Receiving your COVID-19 vaccine without delay is important (regardless of whether you drink or not)</li> <li>• You may like to reduce your alcohol consumption as this is generally good for your health and there is limited evidence that it might improve your body's response to the vaccine.</li> </ul> <p><sup>a</sup> <a href="https://www.drinkaware.co.uk/news/drinkaware-issues-precautionary-advice-about-alcohol-and-the-covid-19-vaccine">https://www.drinkaware.co.uk/news/drinkaware-issues-precautionary-advice-about-alcohol-and-the-covid-19-vaccine</a> (18 January 2021)</p>
-------------	---

## 9 Other questions

9.1 Implications for blood donation	<p>Please wait 7 full days from your vaccine before donating on the 8th day. If you had side effects from the vaccine such as headache, temperature, aches and chills please wait 28 days from your recovery. <sup>a</sup></p> <p><sup>a</sup> <a href="https://www.blood.co.uk/news-and-campaigns/news-and-statements/coronavirus-covid-19-updates/">https://www.blood.co.uk/news-and-campaigns/news-and-statements/coronavirus-covid-19-updates/</a></p>
-------------------------------------	--

## 10 Management of patients recruited into trials

### 10.1 COV002 (Oxford) trial

Participant need to unblind to understand their options<sup>4</sup>:

- <https://apps.ovg.ox.ac.uk/login/>
- Login is their participant number. Password is their DOB as an 8 digit number (DDMMYYYY)

Control arm (MenACWY vaccine)	<ul style="list-style-type: none"><li>• Receive national rollout vaccine as normal (2 doses of vaccine)</li><li>• A 2 week gap is recommended between the last dose of control vaccine and the national rollout vaccine</li></ul>
One dose of ChAdOx1 vaccine (either low or standard dose)	<ul style="list-style-type: none"><li>• Receive one dose of national rollout vaccine</li><li>• A 3 week gap is recommended between the last dose of ChAdOx1 vaccine and the national rollout vaccine</li></ul>
Two doses of ChAdOx1 vaccine (either low:low or low:standard)	<ul style="list-style-type: none"><li>• No need to have the national rollout vaccine</li></ul>

**Participants who were advised to not receive a booster dose of the trial vaccine should contact the site to discuss options before having a COVID-19 vaccine as part of the national rollout.**

### 10.2 COVAC1 (Imperial) trial

All participants should receive national rollout vaccine as normal (2 doses of vaccine). A 4 week gap is recommended between the last dose of COVAC vaccine and the national rollout vaccine.

### 10.3 NOVOVAX trial

Participants are asked to contact the trials team to be unblinded before they make an appointment for a vaccine.

#### 10.4 ENSEMBLE2 trial (Janssen; Johnson & Johnson; Ad26.COV2.S)

Participants need to unblind to understand their options therefore are asked to contact their trials team. Evidence of unbinding is needed before national rollout vaccine should be given.

Control arm (placebo)	Either: i. Enrol onto the ENSEMBLE2 open label crossover study (subject to trial protocol amendment), or ii. Receive national rollout vaccine as normal (2 doses of AZ/Pfizer/Moderna vaccine)
Ad26.COV2.S vaccine arm (1 or 2 doses)	Either: i. No national rollout vaccine (EMA has licensed the vaccine based on a single-dose regimen), or ii. Receive one dose of national rollout vaccine (anyone receiving a trial vaccine, is eligible for a single dose of national rollout vaccine, but the safety/efficacy of combining different regimens is not known). An 4 week gap is recommended between the last dose of Ad26.COV2.S vaccine and the national rollout vaccine.

#### 10.5 Cov-Compare trial (Valneva; VLA2001)

Participants in the over 30s cohort need to unblind to understand their options, therefore are asked to contact their trials team. Evidence of unbinding is needed before national rollout vaccine should be given. Participants in the under 30s cohort do not require unblinding, as they will all have received the Valneva vaccine.

Valneva vaccine (VLA2001)	<ul style="list-style-type: none"> <li>• Receive national rollout vaccine as normal</li> <li>• A 2 week gap is recommended between the last dose of control vaccine and the national rollout vaccine</li> </ul>
One dose of AstraZeneca vaccine (AZD1222)	<ul style="list-style-type: none"> <li>• Receive one dose of national rollout vaccine</li> <li>• A 3 week gap is recommended between the last dose of AZD1222 vaccine and the national rollout vaccine</li> </ul>
Two doses of AstraZeneca vaccine (AZD1222)	<ul style="list-style-type: none"> <li>• No need to have the national rollout vaccine</li> </ul>

## 10.6 COM-COV2

Participants will be contacted by their trials team to discuss options. An additional dose is not clinically indicated, however may be useful for travel passports. Those wishing to receive this additional dose will be provided with a letter to give to their vaccination centre.

## 10.7 Novavax study

Participants will be contacted by their trials team to discuss options. Those patients who require an additional dose will likely be booked into local vaccination hub (in Chel West).<sup>5</sup>

## 11 Vaccine brands available nationally and internationally

The table below lists vaccine manufacturers and associated vaccine names. It is intended to support pharmacy staff in identifying which vaccine a given patient has already been received.

When the vaccine is identified, follow Public Health England's advice relating to foreign vaccine administration (Appendix 1).

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1009174/COVID-19\\_vaccination\\_programme\\_guidance\\_for\\_healthcare\\_workers\\_6\\_August\\_2021\\_v3.10.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009174/COVID-19_vaccination_programme_guidance_for_healthcare_workers_6_August_2021_v3.10.pdf)

Manufacturer	Vaccines names
Sinovac Life Sciences Co., Ltd (Beijing <sup>6</sup> )	<ul style="list-style-type: none"> <li>• Vero Cell<sup>7</sup> <b>[be aware that another vaccine may also be called Vero Cell, see below]</b></li> <li>• CoronaVac<sup>8</sup></li> <li>• Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute<sup>9</sup></li> </ul>
CureVac AG	<ul style="list-style-type: none"> <li>• CVnCoV<sup>7</sup></li> <li>• CV07050101<sup>10</sup></li> </ul>
Novavax CZ AS	<ul style="list-style-type: none"> <li>• NVX-CoV2373<sup>7</sup></li> </ul>
Russia's Gamaleya National Centre of Epidemiology and Microbiology	<ul style="list-style-type: none"> <li>• Sputnik V<sup>7</sup></li> <li>• Gam-COVID-Vac<sup>7</sup></li> <li>• rAd26-S<sup>11</sup></li> <li>• rAd5-S<sup>11</sup></li> <li>• Gam-COVID-Vac<sup>11</sup></li> </ul>
Pfizer-BioNTech	<ul style="list-style-type: none"> <li>• Comirnaty<sup>12</sup></li> <li>• Tozinameran<sup>13</sup></li> <li>• BNT162b2<sup>14</sup></li> </ul>
Janssen (also Johnson & Johnson <sup>15</sup> )	<ul style="list-style-type: none"> <li>• COVID-19 Vaccine Janssen<sup>12</sup></li> <li>• Ad26.COV2.S<sup>16</sup></li> <li>• JNJ-78436735<sup>16</sup></li> <li>• VAC31518<sup>17</sup></li> <li>• Ad26COVS1<sup>18</sup></li> </ul>

Moderna (also Takeda <sup>19</sup> )	<ul style="list-style-type: none"> <li>• COVID-19 Vaccine Moderna<sup>12</sup></li> <li>• Spikevax<sup>1</sup></li> <li>• mRNA-1273<sup>20</sup></li> <li>• TAK-919<sup>19</sup></li> </ul>
AstraZeneca (Institute of India Covishield <sup>21</sup> )	<ul style="list-style-type: none"> <li>• Vaxzevria<sup>12</sup></li> <li>• COVID-19 Vaccine AstraZeneca<sup>12</sup></li> <li>• ChAdOx1-S<sup>14</sup></li> <li>• AZD1222<sup>22</sup></li> </ul>
Sinopharm (China National Pharmaceutical Group <sup>23</sup> ) – Beijing <sup>6,24</sup>	<ul style="list-style-type: none"> <li>• Inactivated COVID-19 vaccine BIBP<sup>23</sup></li> <li>• BBIBP-CorV<sup>23,24</sup></li> </ul> <p><i>PHE have advised that both Sinopharm vaccines should be managed in the same way.</i></p>
Sinopharm (China National Pharmaceutical Group) - Wuhan <sup>6,25</sup>	<ul style="list-style-type: none"> <li>• Vero Cells<sup>25</sup> <b>[be aware that another vaccine may also be called Vero Cell, see above and below]</b></li> </ul> <p><i>PHE have advised that both Sinopharm vaccines should be managed in the same way.</i></p>
CanSino Biologics	<ul style="list-style-type: none"> <li>• Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)<sup>26</sup></li> <li>• Ad5-nCoV<sup>26</sup></li> <li>• Convidecia<sup>27</sup></li> <li>• PakVac<sup>28</sup></li> </ul>
Bharat Biotech	<ul style="list-style-type: none"> <li>• Covaxin<sup>29</sup></li> <li>• BBV152<sup>30</sup></li> </ul>

The list of manufacturers was taken from the EMA website and the Public Health England 'COVID-19 vaccination programme Information for healthcare practitioners' document

The above list is not extensive and other vaccine are available in other countries, see below link for further information:

<https://covid19.trackvaccines.org/vaccines/>

## 12 Document management

This document is subject to constant review. If you identify any information that needs to be updated please contact [admin.ncl-mon@nhs.uk](mailto:admin.ncl-mon@nhs.uk).

## 13 Version history

Date	Version	Amendments
10 Aug 2021	1.0	New document (merges three separate documents into one)
29 Oct 2021	1.1	Major revision of vaccine eligible section (2.4, <b>Error! Reference source not found.</b> , 2.5, 2.6 and 2.7). R eference checks and minor edits throughout.



## References

1. Public Health England. COVID-19: The Green Book, Chapter 14a. Published online September 16, 2021. <https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a>
2. Medicines and Healthcare Regulatory Agency. Summary of Product Characteristics for Vaxzevria (formerly AstraZeneca vaccine). Published online October 21, 2021. <https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca>
3. NHS England & NHS Improvement. Covid-19 frequently asked questions (v6). Published online August 2021. <https://www.england.nhs.uk/london/our-work/covid-19-vaccine-communication-materials/>
4. COV002 (Oxford) trial. IRAS Project ID: 281904 REC Ref: 20/SC/0179 COV002 Participant Email and Online Unblinding Form version 1.0. Published online December 8, 2020.
5. Research & Development - Chelsea and Westminster Hospital J (Clinical RN. Fw: Novavax trial. Published online October 13, 2021.
6. Mallapaty S. China's COVID vaccines are going global — but questions remain. *Nature*. 2021;593(7858):178-179. doi:10.1038/d41586-021-01146-0
7. European Medicines Agency. COVID-19 vaccines: under evaluation. European Medicines Agency. Published January 11, 2021. Accessed June 23, 2021. <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-under-evaluation>
8. ClinicalTrials.gov. *An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine (Projeto S)*.; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04747821>
9. ClinicalTrials.gov. *Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine*.; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04845048>
10. ClinicalTrials.gov. *A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 MRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19*.; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04838847>
11. ClinicalTrials.gov. *Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan*.; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04871841>

12. European Medicines Agency. COVID-19 vaccines: authorised. European Medicines Agency. Published January 11, 2021. Accessed June 23, 2021. <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised>
13. COVID19 Vaccine Tracker. Pfizer/BioNTech: BNT162b2 – COVID19 Vaccine Tracker. Accessed June 23, 2021. <https://covid19.trackvaccines.org/vaccines/6/>
14. ClinicalTrials.gov. *Heterologous Vaccination With an Vaxzevria (ChAdOx1-S) Prime and a Comirnaty (BNT162b2) Boost Compared With Homolog Vaccination With Vaxzevria (Prime/Boost) or Comirnaty (Prime/Boost).*; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04907331>
15. Centres for Disease Control and Prevention. Information about the J&J/Janssen COVID-19 Vaccine. Centers for Disease Control and Prevention. Published June 1, 2021. Accessed June 23, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html>
16. ClinicalTrials.gov. *A Study of Ad26.COV2.S in Adults (COVID-19).*; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04509947>
17. ClinicalTrials.gov. *A Study of Ad26.COV2.S in Healthy Adults (COVID-19).*; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04894305>
18. ClinicalTrials.gov. *A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1).*; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04765384>
19. COVID19 Vaccine Tracker. Takeda: TAK-919 – COVID19 Vaccine Tracker. Accessed June 23, 2021. <https://covid19.trackvaccines.org/vaccines/79/>
20. ClinicalTrials.gov. *A Study to Evaluate Efficacy, Safety, and Immunogenicity of MRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19.*; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04470427>
21. Serum Institute of India PVT. LTD. COVISHIELD FAQs. Published online May 21, 2021. Accessed June 23, 2021. [https://www.seruminstitute.com/health\\_faq\\_covishield.php#faq1](https://www.seruminstitute.com/health_faq_covishield.php#faq1)
22. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet*. Published online December 2020:S0140673620326611. doi:10.1016/S0140-6736(20)32661-1

23. World Health Organisation. The Sinopharm COVID-19 vaccine: What you need to know. Accessed June 23, 2021. <https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know>
24. COVID19 Vaccine Tracker. Sinopharm (Beijing): BBIBP-CorV. Accessed June 23, 2021. <https://covid19.trackvaccines.org/vaccines/5/>
25. COVID19 Vaccine Tracker. Sinopharm (Wuhan): Inactivated (Vero Cells). Accessed June 25, 2021. <https://covid19.trackvaccines.org/vaccines/16/>
26. ClinicalTrials.gov. *Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above.*; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04526990>
27. COVID19 Vaccine Tracker. CanSino: Ad5-nCoV – COVID19 Vaccine Tracker. Accessed June 23, 2021. <https://covid19.trackvaccines.org/vaccines/2/>
28. Pakistan produces Chinese CanSinoBio COVID vaccine, brands it PakVac. Reuters. Published June 4, 2021. Accessed June 23, 2021. <https://www.reuters.com/world/asia-pacific/pakistan-produces-chinese-cansinobio-covid-vaccine-brands-it-pakvac-2021-06-04/>
29. Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. *Lancet Infect Dis.* 2021;0(0). doi:10.1016/S1473-3099(21)00070-0
30. ClinicalTrials.gov. *An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers.*; 2021. Accessed June 21, 2021. <https://clinicaltrials.gov/ct2/show/NCT04641481>